V
Vlado Perkovic
Researcher at The George Institute for Global Health
Publications - 438
Citations - 39418
Vlado Perkovic is an academic researcher from The George Institute for Global Health. The author has contributed to research in topics: Kidney disease & Diabetes mellitus. The author has an hindex of 83, co-authored 378 publications receiving 29624 citations. Previous affiliations of Vlado Perkovic include University of Queensland & Royal North Shore Hospital.
Papers
More filters
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
Journal ArticleDOI
Worldwide access to treatment for end-stage kidney disease: a systematic review.
Thaminda Liyanage,Thaminda Liyanage,Toshiharu Ninomiya,Vivekanand Jha,Vivekanand Jha,Vivekanand Jha,Bruce Neal,Halle Marie Patrice,Ikechi G. Okpechi,Ming hui Zhao,Jicheng Lv,Amit X. Garg,John Knight,Anthony Rodgers,Martin Gallagher,Sradha Kotwal,Alan Cass,Alan Cass,Vlado Perkovic,Vlado Perkovic +19 more
TL;DR: The large number of people receiving RRT and the substantial number without access to it show the need to both develop low-cost treatments and implement effective population-based prevention strategies.
Journal ArticleDOI
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Min Jun,Celine Foote,Jicheng Lv,Jicheng Lv,Bruce Neal,Anushka Patel,Stephen J. Nicholls,Diederick E. Grobbee,Alan Cass,John Chalmers,Vlado Perkovic +10 more
TL;DR: Fibrates can reduce the risk of major cardiovascular events predominantly by prevention of coronary events, and might have a role in individuals at high risk of cardiovascular events and in those with combined dyslipidaemia.
Journal ArticleDOI
Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
Toshiharu Ninomiya,Vlado Perkovic,Bastiaan E. de Galan,Bastiaan E. de Galan,Sophia Zoungas,Avinesh Pillai,Meg Jardine,Anushka Patel,Alan Cass,Bruce Neal,Neil R Poulter,Carl-Eric Mogensen,Mark E. Cooper,Michel Marre,Bryan Williams,Pavel Hamet,Giuseppe Mancia,Mark Woodward,Mark Woodward,Stephen MacMahon,John Chalmers +20 more
TL;DR: In this article, the effects of albuminuria and reduced estimated GFR (eGFR) on the risk for cardiovascular and renal events among individuals with type 2 diabetes were investigated. But, there was no evidence of an interaction between the effect of higher eGFR and lower UACR.